ORGS (Orgenesis) Cyclically Adjusted FCF per Share: $0.00 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGS Orgenesis Inc ORGS
12 GF Score
Price $0.59
View Full Analysis

What is Orgenesis Cyclically Adjusted FCF per Share?

Orgenesis ORGS +490.00% 12 Cyclically Adjusted FCF per Share is $0.00 as of Dec. 2024. GuruFocus rates ORGS with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Orgenesis's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.417. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-24), Orgenesis's current stock price is $0.59. Orgenesis's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $0.00. Orgenesis's Cyclically Adjusted Price-to-FCF of today is .


Orgenesis  (OTCPK:ORGS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Orgenesis Cyclically Adjusted FCF per Share Related Terms


Orgenesis Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Orgenesis's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Cyclically Adjusted FCF per Share Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.07 -12.24 -14.19 -14.66 0.00

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.66 -14.91 -15.03 -15.13 0.00

ORGS vs ENDV, GBLX, OMGAQ: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted Price-to-FCF falls into.


ORGS
12GF Score
Orgenesis Inc ORGS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orgenesis's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.417/315.6050*315.6050
=-0.417

Current CPI (Dec. 2024) = 315.6050.

Orgenesis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201502 -1.380 234.722 -1.856
201505 -1.174 237.805 -1.558
201508 -2.728 238.316 -3.613
201511 -2.452 237.336 -3.261
201602 -1.973 237.111 -2.626
201605 -1.314 240.229 -1.726
201608 -1.458 240.849 -1.911
201611 -1.425 241.353 -1.863
201702 0.157 243.603 0.203
201705 -2.496 244.733 -3.219
201708 -1.763 245.519 -2.266
201711 -0.708 246.669 -0.906
201802 -2.453 248.991 -3.109
201805 -5.247 251.588 -6.582
201808 -5.128 252.146 -6.419
201811 -2.858 252.038 -3.579
201903 -3.564 254.202 -4.425
201906 -3.388 256.143 -4.175
201909 -3.535 256.759 -4.345
201912 -5.425 256.974 -6.663
202003 -8.094 258.115 -9.897
202006 -4.375 257.797 -5.356
202009 -4.664 260.280 -5.655
202012 -19.045 260.474 -23.076
202103 -2.099 264.877 -2.501
202106 -5.134 271.696 -5.964
202109 -4.190 274.310 -4.821
202112 -2.873 278.802 -3.252
202203 -1.502 287.504 -1.649
202206 -3.974 296.311 -4.233
202209 -2.983 296.808 -3.172
202212 -6.343 296.797 -6.745
202303 -3.219 301.836 -3.366
202306 -2.247 305.109 -2.324
202309 -0.493 307.789 -0.506
202312 -0.167 306.746 -0.172
202403 -1.400 312.332 -1.415
202406 -1.520 314.175 -1.527
202409 -0.994 315.301 -0.995
202412 -0.417 315.605 -0.417

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
Orgenesis (ORGS) has a Cyclically Adjusted FCF per Share of $0.00 as of Dec. 2024. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orgenesis and its competitors.
Is Orgenesis' Cyclically Adjusted FCF per Share too high?
Orgenesis' current Cyclically Adjusted FCF per Share is $0.00. Overall, Orgenesis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Orgenesis' Cyclically Adjusted FCF per Share compare to ENDV and GBLX?
Orgenesis' Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orgenesis and its competitors. Orgenesis's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orgenesis stock overvalued right now?
Orgenesis (ORGS) has a current Cyclically Adjusted FCF per Share of $0.00. The current Cyclically Adjusted FCF per Share is $0.00. Orgenesis' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Orgenesis (ORGS), the current Cyclically Adjusted FCF per Share is $0.00 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for ORGS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price